Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-3510 (Inovio Pharmaceuticals, Inc.)
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
INO-3510 is a multi-plasmid DNA vaccine developed by Inovio Pharmaceuticals for the prevention of influenza. It is a combination product consisting of three distinct DNA plasmids: INO-3605, INO-3609, and INO-3401. These plasmids encode for hemagglutinin (HA) antigens derived from H1 and H5 influenza A virus strains. The vaccine is administered intradermally followed by in vivo electroporation using Inovio's proprietary CELLECTRA device, which facilitates the entry of the DNA plasmids into host cells. Once inside, the host cell machinery expresses the viral antigens, triggering both cellular (T-cell) and humoral (B-cell/antibody) immune responses. INO-3510 was evaluated in Phase I clinical trials to assess its safety and immunogenicity against seasonal and potentially pandemic influenza strains.
- Other names
- seasonal influenza vaccine-Inovio Pharmaceuticals-influenza
02
Targets
HA (Hemagglutinin)H5 HA (Influenza A hemagglutinin H5)
Beyond the preview
Go deeper on INO-3510 (Inovio Pharmaceuticals, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-3510 (Inovio Pharmaceuticals, Inc.).